Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Alliance Grants

University of Toronto

$148,800.00

Deep single-cell omics investigation of antibody-producing cells

EF 2023-24

Résumé
Therapeutic antibodies are a rapidly growing class of molecules used to treat human disease. Indeed, a recent study on therapeutic antibody use in Ontarian cancer patients found that the frequency of antibody treatment rose over 10-fold in only 8-years. Most therapeutic antibodies are grown in a particular cell type derived from hamsters, called CHO cells. In best case scenarios, CHO cells can produce astounding amounts of antibody therapeutics, when grown in massive cultures of tens to hundreds of litres. However, in many cases CHO cells struggle to produce usable quantities of antibodies, driving up the cost of cell line development massively. Here, a team of researchers in academia and industry propose to work together to optimize this process. Specifically, microfluidics experts the University of Toronto (U of T) have invented a novel platform that permits the acquisition of deep biological insights from single cells. The platform includes a microscope, a fluidics device, and a highly precise laser shot. The laser is used to break open a particular cell of interest, and the fluidics device allows collection of the "guts" of the targeted cell for analysis. In this project, the U of T group will team up with researchers at Amgen, a market leader in the development of therapeutic antibodies. The two groups will work together to generate valuable datasets on the underlying causes of low productivity CHO cells. Further, the team will develop exciting new methods to pair with the fluidic technology, like fluorescent labelling of CHO cell productivity, and machine-learning based identification of highly productive cells. This project will yield exciting new technologies developed in Canada and help drive down the cost of producing next generation biotherapeutics.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
590446-2023
Name nom
Wheeler, Aaron AR
Department département
Chemistry (St. George Campus)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2023
Award amount
148800
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5100
Research subject group en
Cell biology
Research subject group fr
Cell biology
Research subject en
Biologie cellulaire
Research subject fr
Biologie cellulaire
Application title
Deep single-cell omics investigation of antibody-producing cells
Keyword
biotherapeutics; immunofluorescence; machine learning; microfluidics; microscopy; proteomics; single-cell omics; transcriptomics
Application summary
Therapeutic antibodies are a rapidly growing class of molecules used to treat human disease. Indeed, a recent study on therapeutic antibody use in Ontarian cancer patients found that the frequency of antibody treatment rose over 10-fold in only 8-years. Most therapeutic antibodies are grown in a particular cell type derived from hamsters, called CHO cells. In best case scenarios, CHO cells can produce astounding amounts of antibody therapeutics, when grown in massive cultures of tens to hundreds of litres. However, in many cases CHO cells struggle to produce usable quantities of antibodies, driving up the cost of cell line development massively. Here, a team of researchers in academia and industry propose to work together to optimize this process. Specifically, microfluidics experts the University of Toronto (U of T) have invented a novel platform that permits the acquisition of deep biological insights from single cells. The platform includes a microscope, a fluidics device, and a highly precise laser shot. The laser is used to break open a particular cell of interest, and the fluidics device allows collection of the "guts" of the targeted cell for analysis. In this project, the U of T group will team up with researchers at Amgen, a market leader in the development of therapeutic antibodies. The two groups will work together to generate valuable datasets on the underlying causes of low productivity CHO cells. Further, the team will develop exciting new methods to pair with the fluidic technology, like fluorescent labelling of CHO cell productivity, and machine-learning based identification of highly productive cells. This project will yield exciting new technologies developed in Canada and help drive down the cost of producing next generation biotherapeutics.